IL17A and psoriasis: Biologic therapies targeting IL-17, including the antibodies secukinumab (IL-17AA and IL-17AF), ixekizumab (IL-17AA and IL-17AF), bimekizumab (IL-17AA, IL-17AF, and IL-17FF), and brodalumab (IL-17 receptor A), are available for the treatment of psoriasis [9–12].